First-in-human study with CRISPR/Cas9-based gene editing in ATTR amyloid cardiomyopathy

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Improved outcomes with rapid uptitration of HF medication after acute HF
Improved outcomes with rapid uptitration of HF medication after acute HF
AHA 2022
Improved outcomes with rapid uptitration of HF medication after acute HF
- Prof. Alexandre Mebazaa, MD, PhD
Composite endpoint of CV death or kidney disease worsening reduced by SGLT2i in CKD
Composite endpoint of CV death or kidney disease worsening reduced by SGLT2i in CKD
AHA 2022
Composite endpoint of CV death or kidney disease worsening reduced by SGLT2i in CKD
- David Preiss, PhD
Dramatic reduction in primary endpoint with precision testing in stable patients with suspected CAD
Dramatic reduction in primary endpoint with precision testing in stable patients with suspected CAD
AHA 2022
Dramatic reduction in primary endpoint with precision testing in stable patients with suspected CAD
- Prof. Pamela Douglas, MD
Head-to-head comparison of two loop diuretics in patients hospitalized with HF
Head-to-head comparison of two loop diuretics in patients hospitalized with HF
AHA 2022
Head-to-head comparison of two loop diuretics in patients hospitalized with HF
- Robert J. Mentz, MD